[
  {
    "ts": null,
    "headline": "Insulet's Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold",
    "summary": "Insulet (PODD) excels with strong Q2 results, Omnipod 5 app launch, and >20% growth outlook. Read here for an investment analysis.",
    "url": "https://finnhub.io/api/news?id=6ac9734d316522607ce829994cef7f92c11fab18e55a0a610cc16fd5499c1fa4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755128996,
      "headline": "Insulet's Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold",
      "id": 136342966,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1752522235/image_1752522235.jpg?io=getty-c-w1536",
      "related": "PODD",
      "source": "SeekingAlpha",
      "summary": "Insulet (PODD) excels with strong Q2 results, Omnipod 5 app launch, and >20% growth outlook. Read here for an investment analysis.",
      "url": "https://finnhub.io/api/news?id=6ac9734d316522607ce829994cef7f92c11fab18e55a0a610cc16fd5499c1fa4"
    }
  },
  {
    "ts": null,
    "headline": "Artisan Mid Cap Fund Q2 2025 Commentary",
    "summary": "Artisan Mid Cap Fund Q2 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=95878696f52a58f98a8b30028fb702fafb40eca96f335aff4d82d32857c23c16",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755126900,
      "headline": "Artisan Mid Cap Fund Q2 2025 Commentary",
      "id": 136342844,
      "image": "",
      "related": "PODD",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=95878696f52a58f98a8b30028fb702fafb40eca96f335aff4d82d32857c23c16"
    }
  },
  {
    "ts": null,
    "headline": "PODD Q2 Deep Dive: Omnipod 5 Adoption and International Expansion Drive Results",
    "summary": "Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 32.9% year on year to $649.1 million. On top of that, next quarter’s revenue guidance ($671.7 million at the midpoint) was surprisingly good and 4.4% above what analysts were expecting. Its non-GAAP profit of $1.17 per share was 26.8% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=f38ebba8e05bb2214488c477c3e1e06733615d8a2cb98c289776e28823d1e2a7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755056407,
      "headline": "PODD Q2 Deep Dive: Omnipod 5 Adoption and International Expansion Drive Results",
      "id": 136328794,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PODD",
      "source": "Yahoo",
      "summary": "Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 32.9% year on year to $649.1 million. On top of that, next quarter’s revenue guidance ($671.7 million at the midpoint) was surprisingly good and 4.4% above what analysts were expecting. Its non-GAAP profit of $1.17 per share was 26.8% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=f38ebba8e05bb2214488c477c3e1e06733615d8a2cb98c289776e28823d1e2a7"
    }
  }
]